Unipharm Trading Ltd

5-α Reductase Inhibitor, α1 Blocker. Dutasteride 0.5 mg, Tamsulosin HCl 0.4 mg.
5-a Reductase Inhibitor/Alpha 1 Blocker. Dutasteride 0.5 mg, tamsulosin 0.4 mg.
CAPS: 30. 1 cap. dly. See lit.
Tmt. mod. to severe symp. BPH. Reduc. risk of acute urin. reten. (AUR) and surgery in pts. with mod. to severe sympt. of BPH.
C/I: Hyperses., women, child., adolesn., pts. with a hist. of orthost. hypotension, pts. with severe hepat. impair.

Dronedarone HCl 400 mg.
FC TABS. 60 x 400 mg: 400 mg twice dly., one with morning meal one with evening meal. See lit.
Maint. of sinus rhythm after successful cardioversion in adult clinically stable pts with paroxysmal or persistent AF.
C/I: Hypersens.; 2^nd or 3rd deg. AV block, complete bundle branch block, distal block, sinus node dysfun., atrial conduct. defects, or sick sinus synd. (ex. when used in conj. with a functioning pacemaker); Bradycardia <50 b/min; Permanent AF with an AF durat. ≥6 mnths (or dur. unknown) and attempts to restore sinus rhythm no long. conside. by physician; pts. in unstable hemodyn. cond.; hist., curr. heart fail. or left ventr. syst. dysfun.; pts. with liver and lung tox. related to prev. use of amiodarone; co-administr. with potent CYP 3A4 inh., med. product. induc. TdP; QTc Bazett interval ≥500 msec.; sev. hepatic impair.; sev. renal impair. (CrCl <30 ml/min); co-administr. with dabigatran. See lit.

Vitamin D2 Analog. Paricalcitol 5 mcg/ml.
Sol. for Inj.: 5 x 1 ml. Init. Dose should be calcul. based on baseline PTH levels, administ. as an IV bolus dose no more frequently then every other day at any time during dialysis. See lit.
Prev. and tmt. of secondary hyperparathyroidism in adult pts with chronic renal failure who are underg. haemodialysis.
C/I: Hypersens., Vit. D toxicity, Hypercalcaemia

Colony Stimulating Factor. Pegfilgrastim 6 mg / 0.6 ml.
PREFILL. SYR.: 1 x 6 mg / 0.6 mL. One 6 mg for ea. chemother. cycle, S.C. inject. at least 24 hrs. after cytotox. chemother. See lit.
Reduct. durat. neutropen., incidence of febrile neutropen. in pts. treat. with cytotox. chemother.at interval. of 14 dys. or more, for malignan. (with the exception of chronic myeloid leukemia and myelodysplastic synd.).
C/I: Hypersens.

Antifibrinolytic. Pirfenidone 267 mg, Pirfenidone 801 mg.
FC tab: 267/801 mg X 90
 Dose to be titr. to 2403 mg/d over a 14-day period as follows:
● Days 1 to 7: a dose of 267 mg admin. 3/d (801 mg/d)
● Days 8 to 14: a dose of 534 mg admin. 3/d (1602 mg/d)
● Day 15 onward: a dose of 801 mg admin. 3/d (2403 mg/d)
maint. dly. dose is 801 mg 3/d with food (total of 2403 mg/d). Doses above 2403 mg/d are not recomm. for any ptt. See lit.
In adlts. for mild to moder. idiopathic pulmon. fibrosis (IPF).
C/I:  Hypersens. Hist. of angioedema with this drug.
Concom. use of fluvoxamine
Sev. hepatic impairm. or end stage liver dis.
Sev. renal impairm. (CrCl <30 ml/min) or end stage renal dis. req. dialysis

SSRI. Fluoxetine HCl 4 mg / 1 ml.
ORAL SOL.: 120 mL. Major Depress. Dis., OCD: init. 20 mg/day. Bulimia Nervosa: init. 60 mg/day. See lit.
Major Depress. Dis., OCD, Bulimia Nervosa.
C/I: Hypersens.; combination irrevers. non-select. MAOI, metoprolol for card. fail.